Contact Us

PW Case Review Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

FDA Tells Pfizer To Pull Bextra Off Market

Apr 7, 2005 | UPI

Food and Drug Administration officials Thursday told Pfizer Inc. to take its COX-2 drug Bextra off the U.S. market and put a warning on Celebrex.

The FDA, based on recommendations from its Arthritis and Drug Safety and Risk Management Advisory Committee following a hearing in February, also asked manufacturers of all other prescription non-steroidal anti-inflammatory drugs to revise their labels to include the same box warning included on Celebrex.

Drugmakers selling NSAIDs also will have to include a medication guide for patients advising them of the potential for adverse events such as heart attack, stroke and gastrointestinal bleeding associated with this class of drugs.

Manufacturers of over-the-counter NSAIDs were asked to include more specific information about potential side effects, including a warning about potential skin reactions.

FDA began to investigate the COX-2 drugs last fall, and then included all NSAIDs, following studies that showed Merck's Vioxx, a COX-2 arthritis drug, doubled a patient's risk of heart attack when taken longer than 18 months.

Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo